This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pedranzini, L. Articles by Bromberg, J. Search for Related Content PubMed PubMed Citation Articles by Pedranzini, L. Articles by Bromberg, J.

Pyridone 6, A Pan-Janus–Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells

¹ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; ² Department of Hematology/Oncology, Technical University of Munich, Munich, Germany; and ³ Division of Experimental Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Jacqueline Bromberg, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 212-639-2577; Fax: 646-422-2231; E-mail: bromberj{at}mskcc.org.

Interleukin-6 (IL-6) and the subsequent Janus-activated kinase (JAK)-dependent signaling pathways play a critical role in the pathogenesis of multiple myeloma. Here, we compared the sensitivity and specificity of a novel pan-JAK inhibitor, tetracyclic pyridone 6 (P6), with that of AG490 in a panel of myeloma-derived cell lines. P6 induced growth arrest and subsequent apoptosis of the IL-6-dependent hybridoma and myeloma-derived cell lines (B9 and INA-6) grown either in IL-6-containing medium or in the presence of bone marrow–derived stromal cells (BMSC) using much lower concentrations of drug and with significantly faster kinetics than AG490. Myeloma-derived cell lines, which either express constitutively activated JAK/signal transducers and activators of transcription (STAT) 3 (U266) or are IL-6 growth stimulated (KMS11), are partially growth inhibited by P6. However, P6 does not inhibit the growth of myeloma-derived cell lines lacking activated JAKs/STATs nor does it inhibit mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase activity compared with AG490, which led to activation of ERK and induced robust apoptosis of all the examined cell lines. Finally, P6 inhibited the growth of primary myeloma patient samples grown in the presence of BMSCs. Thus, P6 is a more sensitive and specific inhibitor of JAK-STAT3 activity compared with AG490 and potently inhibited the growth of primary myeloma cells and myeloma-derived cell lines grown on BMSCs. (Cancer Res 2006; 66(19): 9714-21)

This article has been cited by other articles:

				S. Kreis, G. A. Munz, S. Haan, P. C. Heinrich, and I. Behrmann Cell Density Dependent Increase of Constitutive Signal Transducers and Activators of Transcription 3 Activity in Melanoma Cells Is Mediated by Janus Kinases Mol. Cancer Res., December 1, 2007; 5(12): 1331 - 1341. [Abstract] [Full Text] [PDF]

				Z. Duan, J. Bradner, E. Greenberg, R. Mazitschek, R. Foster, J. Mahoney, and M. V. Seiden 8-Benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic Acid (SD-1008), a Novel Janus Kinase 2 Inhibitor, Increases Chemotherapy Sensitivity in Human Ovarian Cancer Cells Mol. Pharmacol., November 1, 2007; 72(5): 1137 - 1145. [Abstract] [Full Text] [PDF]

				F. M. Johnson, B. Saigal, H. Tran, and N. J. Donato Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects Clin. Cancer Res., July 15, 2007; 13(14): 4233 - 4244. [Abstract] [Full Text] [PDF]